FDA grants IND clearance for Phase I trials of Phanes’ cancer antibody

FDA grants IND clearance for Phase I trials of Phanes’ cancer antibody

Submitted by admin on October 17, 2022 - 10:31am
Source: 
Clinical Trials Arena
News Tags: 
Phanes Therapeutics
PT217
FDA
small cell lung cancer
Headline: 
FDA grants IND clearance for Phase I trials of Phanes’ cancer antibody
snippet: 


The US Food and Drug Administration (FDA) has granted clearance for Phanes Therapeutics’ Investigational New Drug (IND) application to begin Phase I clinical trials of antibody PT217 to treat small cell lung cancer (SCLC) and other neuroendocrine cancer patients.

Do Not Allow Advertisers to Use My Personal information